Early diagnosis is essential for improved patient management and prognosis.1,2
Thrombosis and renal failure are leading causes of death.3,4
Study description: Researchers followed 80 consecutive patients with PNH referred to Hammersmith Hospital in London, United Kingdom.3 The patients were treated with supportive measures such as oral anticoagulant therapy after established thromboses and transfusions.
PNH, paroxysmal nocturnal haemoglobinuria
Diagnosis is typically delayed from 1 to more than 10 years.5
Identify patients with PNH early within high-risk groups1,3-20
aAnaemia, neutropenia, thrombocytopenia or pancytopenia; bUnusual sites include hepatic veins (Budd-Chiari syndrome), other intra-abdominal veins (portal, splenic, splanchnic), cerebral sinuses and dermal veins; cDetects PNH cells down to a 0.01% clone size
IDA, iron deficiency anaemia; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome
The information on this page is intended as an educational resource for healthcare professionals. It does not replace a healthcare provider’s professional judgement or clinical diagnosis.
Nearly 1 in 5 patients (19%) with haemolytic anaemia have a PNH clone21
Almost half of patients (45%) with aplastic anaemia have a PNH clone21
In PNH, 40–67% of deaths are due to venous or arterial thrombosis20
High-sensitivity flow cytometry is the gold standard for PNH testing: rapid, accurate and highly reliable1,22,23
Prepare your sample
Specimen source – Peripheral blood (not bone marrow)
Sample volume – 1–3 mL
Maximum sample age – Within 48 h of collection
Sample storage – 4°C after 24 h
Anticoagulant – Ethylenediaminetetraacetic acid, heparin or anticoagulant citrate dextrose
Cell lineages – White blood cell tests most accurately reflect PNH clone size1,19
Request a clear report
It is essential for appropriate clinical decisions1,22
When ordering a PNH flow cytometry, request:1,22,24
Clear terminology: minor or significant ‘GPI-deficient population’ versus ‘no detectable level’
Size of GPI-deficient population for each cell lineage tested and proportion of Type II and Type III PNH clones
Sensitivity level used for each lineage tested
Previous flow results to monitor change of clone size over time
Indications for further testing
Monitor your PNH patients
Clone size increased in 40% (10/25) of patients with PNH clone size between 0.11% and 10%25
International PNH Interest Group (IPIG) recommends routine monitoring every 6 to 12 months of patients who have an identified clone26
International Clinical Cytometry Society guidelines, consensus guidelines and the IPIG recommend continued monitoring of patients at higher risk for PNH1,22,26
We are using cookies to give you the best experience on our website.
You can find out more about which cookies we are using or switch them off in settings.
You can adjust all of your cookie settings by navigating the tabs on the left hand side.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!